- Home
- NGNE vs LTBR Comparison
NGNE vs LTBR Comparison
Compare NGNE & LTBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- LTBR
- Stock Information
- Founded
- NGNE 2003
- LTBR 1992
- Country
- NGNE United States
- LTBR United States
- Employees
- NGNE N/A
- LTBR N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- LTBR Professional Services
- Sector
- NGNE Health Care
- LTBR Consumer Discretionary
- Exchange
- NGNE Nasdaq
- LTBR Nasdaq
- Market Cap
- NGNE 325.3M
- LTBR 397.8M
- IPO Year
- NGNE N/A
- LTBR N/A
- Fundamental
- Price
- NGNE $18.48
- LTBR $15.13
- Analyst Decision
- NGNE Strong Buy
- LTBR
- Analyst Count
- NGNE 7
- LTBR 0
- Target Price
- NGNE $41.86
- LTBR N/A
- AVG Volume (30 Days)
- NGNE 110.1K
- LTBR 1.5M
- Earning Date
- NGNE 08-11-2025
- LTBR 08-11-2025
- Dividend Yield
- NGNE N/A
- LTBR N/A
- EPS Growth
- NGNE N/A
- LTBR N/A
- EPS
- NGNE N/A
- LTBR N/A
- Revenue
- NGNE N/A
- LTBR N/A
- Revenue This Year
- NGNE N/A
- LTBR N/A
- Revenue Next Year
- NGNE N/A
- LTBR N/A
- P/E Ratio
- NGNE N/A
- LTBR N/A
- Revenue Growth
- NGNE N/A
- LTBR N/A
- 52 Week Low
- NGNE $6.88
- LTBR $2.24
- 52 Week High
- NGNE $74.49
- LTBR $18.80
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- LTBR 52.17
- Support Level
- NGNE $19.59
- LTBR $12.93
- Resistance Level
- NGNE $20.46
- LTBR $16.19
- Average True Range (ATR)
- NGNE 1.23
- LTBR 1.48
- MACD
- NGNE -0.20
- LTBR -0.02
- Stochastic Oscillator
- NGNE 13.37
- LTBR 37.48
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.